Xilio Therapeutics (XLO) Price to FCF (2021 - 2026)

Xilio Therapeutics has disclosed Price to FCF across 6 years of filings, most recently posting 9.9 for Q2 2026.

• In Q2 2026, Price to FCF fell 120.49% year-over-year to 9.9; the TTM figure through Jun 2026 stood at 3.03 (up 36.31% YoY), while the FY2025 annual figure was 13.6, down 473.0% from the prior year.
• Price to FCF came in at 9.9 for Q2 2026 at Xilio Therapeutics, down from 6.0 in the prior quarter.
• In the past five years, Price to FCF ranged from a high of 2.74 in Q2 2024 to a low of 35.8 in Q4 2025.
• Average Price to FCF over 5 years is 5.72, with a median of 4.12 recorded in 2022.
• The largest YoY upside for Price to FCF was 165.85% in 2025 against a maximum downside of 1060.22% in 2025.
• Over 5 years, Price to FCF stood at 3.94 in 2022, then soared by 71.29% to 1.13 in 2023, then tumbled by 172.83% to 3.09 in 2024, then slumped by 1060.22% to 35.8 in 2025, then surged by 72.35% to 9.9 in 2026.
• Per Business Quant data, the three most recent Price to FCF figures were 9.9 in Q2 2026, 6.0 in Q1 2026, and 35.8 in Q4 2025.